Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance

References

• Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–2972.
   PubMed Web of Science ®Google Scholar
• Abraham J, Salama NN, Azab AK. The role of P-glycoprotein in drug resistance in multiple myeloma. Leuk Lymphoma. 2015;56:26–33.
   PubMed Web of Science ®Google Scholar
• Kaye SB, Kerr DJ. Multidrug resistance: clinical relevance in haematological malignancies. Blood Rev. 1991;5:38–41.
   PubMed Web of Science ®Google Scholar
• Krishnan SR, Jaiswal R, Brown RD, et al. Multiple myeloma and persistence of drug resistance in the age of novel drugs. Int J Oncol. 2016;49:33–50.
   PubMed Web of Science ®Google Scholar
• Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993;81:490–495.
   PubMed Web of Science ®Google Scholar
• Linsenmeyer ME, Jefferson S, Wolf M, et al. Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer. 1992;65:471–475.
   PubMed Web of Science ®Google Scholar
• Nuessler V, Gieseler F, Gullis E, et al. Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease. Leukemia. 1997;11 Suppl 5:S10–S14.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Durie BG, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet. 1992;340:255–259.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Sonneveld P, Schoester M, et al. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. JCO. 1994;12:115–119.
   PubMed Web of Science ®Google Scholar
• Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 1970;30:1174–1184.
   PubMed Web of Science ®Google Scholar
• Szakacs G, Hall MD, Gottesman MM, et al. Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev. 2014;114:5753–5774.
   PubMed Web of Science ®Google Scholar
• Klepsch F, Jabeen I, Chiba P, et al. Pharmacoinformatic approaches to design natural product type ligands of ABC-transporters. CPD. 2010;16:1742–1752.
   Google Scholar
• Bikadi Z, Hazai I, Malik D, et al. Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein. PLoS One. 2011;6:e25815.
   PubMed Web of Science ®Google Scholar
• Fox E, Widemann BC, Pastakia D, et al. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. 2015;76:1273–1283.
   PubMed Web of Science ®Google Scholar
• Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001;61:749–758.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res. 2009;15:7471–7478.
   PubMed Web of Science ®Google Scholar
• Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007;26:241–248.
   PubMed Web of Science ®Google Scholar
• Shannon AM, Bouchier-Hayes DJ, Condron CM, et al. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treatment Rev. 2003;29:297–307.
   PubMed Web of Science ®Google Scholar
• Azab AK, Hu J, Quang P, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012;119:5782–5794.
   PubMed Web of Science ®Google Scholar
• Muz B, de la Puente P, Azab F, et al. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer J. 2014;4:e262.
   PubMed Web of Science ®Google Scholar
• Chen J, Ding Z, Peng Y, et al. HIF-1alpha inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein. PLoS One. 2014;9:e98882.
   PubMed Web of Science ®Google Scholar
• Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62:3387–3394.
   PubMed Web of Science ®Google Scholar
• Li J, Shi M, Cao Y, et al. Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun. 2006;342:1341–1351.
   PubMed Web of Science ®Google Scholar
• Gutman D, Morales AA, Boise LH. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. Leukemia. 2009;23:2181–2183.
   PubMed Web of Science ®Google Scholar
• Hawley TS, Riz I, Yang W, et al. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 2013;88:265–272.
   PubMed Web of Science ®Google Scholar
• Rumpold H, Salvador C, Wolf AM, et al. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun. 2007;361:549–554.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Mitsiades C, et al. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther. 2005;4:686–692.
   PubMed Web of Science ®Google Scholar
• Ao L, Wu Y, Kim D, et al. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol Pharm. 2012;9:2197–2205.
   PubMed Web of Science ®Google Scholar
• Lonial S, Yellapantula VD, Liang W, et al. Interim analysis of the MMRF CoMMpass Trial: identification of novel rearrangements potentially associated with disease initiation and progression. Blood. 2014;124:722.
   Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–2028.
   PubMed Web of Science ®Google Scholar
• Walker J, Martin C, Callaghan R. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer. 2004;40:594–605.
   PubMed Web of Science ®Google Scholar
• Imai T, Muz B, Yeh CH, et al. Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy. Cancer Biol Ther. 2017;18:101–105.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29:625–634.
   PubMed Web of Science ®Google Scholar
• Lehnert M, Dalton WS, Roe D, et al. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood. 1991;77:348–354.
   PubMed Web of Science ®Google Scholar
• Aouali N, Eddabra L, Macadre J, et al. Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol. 2005;56:61–70.
   PubMed Web of Science ®Google Scholar
• Sugie M, Asakura E, Zhao YL, et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother. 2004;48:809–814.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Robey RW, Chen CC, et al. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors. Oncologist. 2012;17:512.
   PubMed Web of Science ®Google Scholar
• Lehne G, Sorensen DR, Tjonnfjord GE, et al. The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia. 2002;16:2388–2394.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Draper D, Chen CC, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. 2011;17:569–580.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sriraman SK, Kenny HA, et al. Reversal of chemoresistance in ovarian cancer by co-delivery of a P-glycoprotein inhibitor and paclitaxel in a liposomal platform. Mol Cancer Ther. 2016;15:2282–2293.
   PubMed Web of Science ®Google Scholar